Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule February 15, 2023 Company Hosted its R&D Day to Discuss Product and Pipeline Goals Across 4 Pipeline Candidates and its Quatramer™ Tumor-Targeting Platform; Multiple inflection points over the next 12-18 Months Company’s Novel Emerging Anti-Cancer Mechanism, Ferroptosis, Addresses Potential Key Target Oncology Markets Projected to reach…

Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer February 13, 2023 HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an…

In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer February 10, 2023 Synergy and crosstalk between Ferroptosis and the Anti-PD-1 Pathways in KRAS G12C-mutated non-small cell lung cancer (NSCLC) cells Lung cancer remains one of the leading causes of…

Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022 March 6th, 2022  Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences professionals and thought leaders Hillstream’s presentation will feature its flagship treatment, HSB-1216, which targets…

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression March 2nd, 2022  HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomas HSB-1216 was recently granted Orphan Drug Designation to treat…

Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma February 16th, 2022 -Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease-  -Evidence implicates ferroptosis, an emerging iron-mediated cell death, as a pathway to effectively eradicate uveal melanoma in proof-of-concept animal…

Hillstream BioPharma Provides Business Review with Key Pipeline Updates February 14th, 2022 Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic  Successful Closing of a $15 million Initial Public Offering on January 14, 2022  R&D Day to Review Novel Emerging Pipeline on February 24, 2022  Bridgewater, NJ – February…

SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022 February 11th, 2022 R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones  Business Review on Monday February 14, 2022 to highlight key program developments  Bridgewater,…

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression February 1st, 2022 Bridgewater, NJ – February 1, 2022 -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging…

Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas January 26th, 2022  Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors  Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in Ferroptosis /…

Hillstream BioPharma Announces Closing of Initial Public Offering January 14th, 2022 Bridgewater, NJ (January 14, 2022) – Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced the closing of its…

Hillstream BioPharma Announces Pricing of Initial Public Offering January 11th, 2022 BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced the…

Hillstream BioPharma and Minotaur Therapeutics Sign Term Sheet to Advance Next-Generation Targeted Knob Biologics for Undruggable Targets August 6th, 2021 Development partnership expected to capitalize upon tumor targeting Quatramersand novel “Knob” biologics Knob biologics with ultra-long CDRs could be effective against undruggable targets Bridgewater, NJ – August 6, 2021 -- Hillstream BioPharma, Inc. (“Hillstream”, the…

Hillstream BioPharma Expands the Scientific Advisory Board with the Addition of Leading Innovator in the Study of Ferroptosis and Cancer, Scott Dixon, Ph.D. July 13, 2021 World leader in the study of iron mediated cell death (IMCD)/ferroptosis, a novel cell death pathway used by cancer cells especially in drug resistant tumors Bridgewater, NJ – July…

Hillstream BioPharma Announces Abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting HSB-1216’s Effect in Triple Negative Breast Cancer (TNBC) June 2nd, 2021 HSB-1216 and a novel anthracycline, pirarubicin, combined and targeted using Quatramer shows synergistic effect in TNBC Bridgewater, NJ – June 2, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today…

Hillstream BioPharma Adds Leading Cancer Drug Development Executive and Features Hillstream’s Quatramer-Based Ferroptosis Inducer, HSB-1216, in Two Abstracts Available for Viewing at AACR 2021 Annual Meeting March 11th, 2021 Lynne A. Bui M.D., leading cancer drug development executive, joins Hillstream BioPharma’s Board of Directors  Abstracts highlight mechanistic and pharmacokinetic data from HSB-1216 in small cell…

Hillstream BioPharma Announces Two Abstracts Accepted for Presentation at AACR 2021 Annual Meeting February 25th, 2021 Abstracts highlight data from HSB-1216 in small cell lung cancer and in combination with low-dose chemotherapy in triple negative breast cancer Bridgewater, NJ – February 25, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the…

Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright January 11th, 2021 Bridgewater, New Jersey - Hillstream BioPharma, Inc. (“Hillstream”), a clinical- stage biotechnology company leveraging its computational intelligence platform to help identify and develop novel therapeutics for rare cancers, announced today that the company will present at the 2021…

Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma November 23rd, 2020 Osteosarcoma remains the most common primary pediatric bone malignancy mostly occurring in adolescents for which treatment has remained essentially unchanged for the past three decades  Osteosarcoma is a highly-aggressive tumor with metastatic disease either at diagnosis or at…